Lung Clinical Trials

USOR #20423

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

USOR #20229

Open-Label, Multicenter Trial of Naptumomab Estanfenatox (NAP) in Combination with Docetaxel Following Obinutuzumab Pretreatment in Subjects with Checkpoint Inhibitor Pretreated Advanced or Metastatic Non-Small Cell Lung Cancer (NT-NAP-102-1: PHASE 2a)